Another hostile takeover bid in the industry – this time by Horizon Pharma plc to grab Depomed Inc. for $29.25 per share in an all-stock, tax-free deal – set Wall Street buzzing, as Horizon offered a 42 percent premium over Monday's closing price of Depomed to make a deal valued at about $3 billion. Read More
DUBLIN – Bavarian Nordic A/S picked up a new $133 million supply contract for its Imvamune smallpox vaccine from the U.S. government, evidence that its infectious disease business continues to prosper, even if cancer immunotherapy is now the company's main value driver. Read More
NEW DELHI – A new report to the government of India suggests the adoption of a slew of measures to help domestic pharma firms, especially small firms that form the bulk of the industry, better understand the global regulatory landscape and meet compliance standards in advanced countries. Read More
HONG KONG – The mechanism by which the thalidomide derivative lenalidomide treats a type of myelodysplastic syndrome (MDS) has been elucidated, reported in the July 1, 2015, edition of Nature, could aid the development of new therapies for leukemias and other malignancies. Read More
Properly reporting and mitigating a potential drug shortage could cost drugmakers up to $40.5 million, the FDA said in a new rule finalizing amendments to its drug shortage reporting requirements. Read More
HONG KONG – A series of enquiries in Australia into tax payments by multinational pharmaceutical companies is likely to have little impact on their operations, particularly outside the country, despite the concern of authorities there. Read More
Oasmia Pharmaceutical AB, of Uppsala, Sweden, said it filed a registration statement on Form F-1/A with the SEC in connection with a proposed public offering of ordinary stock and a listing on Nasdaq under the ticker OASM. Read More
Ignyta Inc., of San Diego, formed a clinical collaboration with the University of California, San Francisco (UCSF), which will study entrectinib in a multicenter, open-label, proof-of-concept trial in patients with metastatic melanoma that is positive for activating alterations in the tyrosine kinase receptors NTRK1/2/3 (encoding TrkA/TrkB/TrkC) or ROS1. Read More
Molecular Partners AG, of Zurich-Schlieren, Switzerland, said its partner Allergan plc, of Dublin, has initiated phase III trials with abicipar pegol for the treatment of wet age-related macular degeneration. Read More
